dasabuvir/ombitasvir/paritaprevir/ritonavir (Viekira XR)
Jump to navigation
Jump to search
Indications
Contraindications
- concurrent use of ethinyl estradiol
- moderate to severe hepatic impairment (Child-Pugh class B & C)
Adverse effects
- fatigue
- asthenia
- nausea,
- insomnia
- pruritus & other skin reactions
- hepatoxicity[3]
- elevated serum transaminases (5-fold elevation in 1%)
- reactivation of hepatitis B in patients with current or previous hepatitis B infection[2]
- 24% of patients with chronic hepatitis B[3]
- 1.4% with resolved hepatitis B infection[3]
Drug interactions
- contraceptives containing ethinyl estradiol increase likelihood of increased serum transaminases
- proton pump inibitors have no effect on efficacy
- drug interaction(s) of antiretroviral protease inhibitor in combination with ritonavir
- drug interaction(s) of boceprevir in combination with ritonavir & Kaletra
- drug interaction(s) of boceprevir in combination with ritonavir & darunavir
- drug interaction(s) of boceprevir in combination with ritonavir & atazanavir
- drug interaction(s) of saquinavir with ritonavir
- drug interaction(s) of eplerenone with ritonavir
Notes
- manufacturer: Abbvie
More general terms
Additional terms
Components
References
- ↑ FDA Approves Single-Tablet Viekira XR for Hepatitis C. Medscape. Jul 26, 2016. http://www.medscape.com/viewarticle/866680
- ↑ 2.0 2.1 FDA Drug Safety Communication: Oct 4, 2016 FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. http://www.fda.gov/Drugs/DrugSafety/ucm522932.htm
- ↑ 3.0 3.1 3.2 3.3 Mucke MM, Backus LI, Mucke VT et al Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterology & Hepatology. Jan 19, 2018 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29371017 <Internet> http://www.thelancet.com/journals/langas/article/PIIS2468-1253(18)30002-5/fulltext